Neurocrine Biosciences Price to Free Cash Flow Ratio 2010-2024 | NBIX

Neurocrine Biosciences current price to free cash flow ratio as of November 08, 2024 is 29.11.

  • Neurocrine Biosciences average price to free cash flow ratio for 2023 was 35.56, a 44.65% decline from 2022.
  • Neurocrine Biosciences average price to free cash flow ratio for 2022 was 64.25, a 85.48% decline from 2021.
  • Neurocrine Biosciences average price to free cash flow ratio for 2021 was 34.64, a 6.07% increase from 2020.

Price to free cash flow ratio can be defined as

Neurocrine Biosciences Price to Free Cash Flow Ratio 2010-2024 | NBIX

  • Neurocrine Biosciences average price to free cash flow ratio for 2023 was 35.56, a 44.65% decline from 2022.
  • Neurocrine Biosciences average price to free cash flow ratio for 2022 was 64.25, a 85.48% decline from 2021.
  • Neurocrine Biosciences average price to free cash flow ratio for 2021 was 34.64, a 6.07% increase from 2020.

Price to free cash flow ratio can be defined as

Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$76.9B
Takeda Pharmaceutical (TAK)$43.9B
Merck (MKKGY)$20.8B
Astellas Pharma (ALPMY)$20.2B
Sandoz Group AG (SDZNY)$19.6B
United Therapeutics (UTHR)$17.7B
Summit Therapeutics (SMMT)$15.4B
Shionogi (SGIOY)$12.3B
Catalent (CTLT)$10.9B
Madrigal Pharmaceuticals (MDGL)$7.4B
Jazz Pharmaceuticals (JAZZ)$6.9B
Orion OYJ (ORINY)$6.8B
Ionis Pharmaceuticals (IONS)$5.7B
Corcept Therapeutics (CORT)$5.7B
Crinetics Pharmaceuticals (CRNX)$4.7B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$3B
Catalyst Pharmaceuticals (CPRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Soleno Therapeutics (SLNO)$2.2B
NewAmsterdam Pharma (NAMS)$2B
Recursion Pharmaceuticals (RXRX)$2B
Centessa Pharmaceuticals (CNTA)$1.8B
Harrow (HROW)$1.7B
Ocular Therapeutix (OCUL)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.6B
Xencor (XNCR)$1.6B
Ardelyx (ARDX)$1.5B
ARS Pharmaceuticals (SPRY)$1.5B